Moderna receives project award through BARDA's rapid response partnership vehicle consortium to accelerate development of mRNA-based pandemic influenza vaccine
Tuesday, July 9, 2024 • 1 PM
Photo courtesy of Moderna
Moderna, Inc. (NASDAQ:MRNA) recently announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines.
